RESEARCH GUIDES
What Is RETA? Retatrutide Research Guide
RETA is shorthand for Retatrutide, also identified by the research code LY3437943. This guide connects the names to primary sources and separates clinical research from the specifications of a catalog item.
Editorial team: JEWJITSU PEPTIDES · Reviewed · Report a correction
RETA, Retatrutide and LY3437943
The full name and research code help identify the correct publication or trial. Lilly describes Retatrutide as one molecule acting on GIP, GLP-1 and glucagon receptors. Triple agonist refers to those three receptor targets, not a mixture of three catalog products.
Reading the TRIUMPH-1 record
ClinicalTrials.gov record NCT05929066 identifies TRIUMPH-1 as a Phase 3 Retatrutide trial. When checked on 15 October 2026, its status was Completed and its last posted update was 21 August 2026. A completed trial is not a marketing authorization.
Review eligibility, the comparison group, planned outcomes and whether results are available. Findings in a defined trial population cannot simply be transferred to every person or to another material sold under the same name.
Research is distinct from medical approval
The Lilly and FDA sources checked on the displayed review date describe Retatrutide as not FDA-approved. A research label, trial code or laboratory certificate does not replace approval of a drug product. Consult the official source for current status rather than relying on a sales label or online summary.
What the product page can tell you
Our Retatrutide page lists labeled strengths, vial counts and available certificates. These are catalog specifications and sample documentation, not clinical-trial findings. Match strength and batch to the report and read its testing method. Price and purity percentages do not measure medical efficacy.